Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children
Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children
复制标题
DOI：
10.3324/haematol.11704
复制
发表时间：
2008-01-31
期刊：
影响因子：
10.1
通讯作者：
Schwinger, Wolfgang
中科院分区：
文献类型：
--
作者：
Lackner, Herwig;Urban, Christian;Schwinger, Wolfgang
儿童癌症治疗期间的噬血细胞性淋巴组织细胞增多症（HLH）是一种罕见的不良事件，给诊断和治疗带来了重大挑战。 1995年至2006年间，6名儿童在接受常规化疗（n-4）或同种异体干细胞移植（n=2）后出现HLH。HLH的治疗包括地塞米松和依托泊苷，2名儿童另外接受英夫利昔单抗或达克珠单抗治疗。3名儿童存活，而3名儿童在诊断HLH后2、5和47天死亡。 HLH 是儿童癌症治疗的严重不良事件。为了克服这种严重的情况，必须尽早诊断并立即开始适当的治疗。
Hemophagocytic lymphohistiocytosis (HLH) during childhood cancer treatment is a rare adverse event posing major diagnostic and therapeutic challenges. Between 1995 and 2006, 6 children developed HLH while on conventional chemotherapy (n-4) or after allogeneic stem cell transplantation (n=2).Treatment of HLH included dexamethasone and etoposide, 2 children additionally received infliximab or daclizumab.Three children survived, whereas 3 children died 2, 5, and 47 days after diagnosis of HLH. HLH is a severe adverse event of childhood cancer therapy. Early diagnosis and immediate initiation of adequate treatment are mandatory to overcome this severe condition.